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Abstract
Background Eosinophilic esophagitis (EoE) is a dis-
ease entity first described in the 1990s, but showing an
increasing incidence that is characterized clinically by
esophageal dysfunction and histologically by a strik-
ing eosinophil infiltration.
Methods This article discusses new aspects of the
pathogenesis, symptoms, diagnosis, and treatment of
EoE.
Results EoE affects both children and adults and is fre-
quently associated with atopic disease and IgE sensiti-
zation. Barrier dysfunction and T-helper 2 inflamma-
tion are considered to be pathogenetically important
factors. Recently, a proton pump inhibitor (PPI)-sen-
sitive EoE subtype as well as an EoE-like disorder have
been described.
Conclusion Research in recent years has contributed
to a better understanding of the disease spectrum and
pathogenesis of EoE, including genetic dispositions,
thereby laying the foundation for innovative treatment
approaches.
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Abbreviations
EETs Eosinophil extracellular (DNA) trap
EoE Eosinophilic esophagitis
GERD Gastroesophageal reflux disease
HPF High-power field
IgE Immunoglobulin E
IL Interleukin
LEKTI Lymphoepithelial Kazal-type-related in-
hibitor
MRNA Messenger ribonucleic acid
PRR Pattern recognition receptor
PPI Proton pump inhibitors
PPI-REE Proton pump inhibitor-responsive esopha-
geal eosinophilia
SNP Single nucleotide polymorphism
TGF Transforming growth factor
TNF Tumor necrosis factor
TSLP Thymic stromal lymphopoietin (cytokine)
Introduction
In the early 1990s, several case series of adult and
pediatric patients with dysphagia accompanied by
eosinophil-rich inflammation on histology were de-
scribed. They were classified as primary or idio-
pathic eosinophilic esophagitis (EoE) and differed
from gastroesophageal reflux disease (GERD) [1, 2].
Our knowledge of EoE has grown continuously since
then, and it is now recognized that we are dealing
with a spectrum of diseases with a complex patho-
genesis. This overview article is intended to discuss
the various clinical and pathogenetic aspects of, and
treatment options for, EoE.
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Table 1 Symptomsand
findings in childrenand
adultswith eosinophilic
esophagitis
Children Adults
Symptoms Abdominal pain Dysphagia
Acid reflux Bolus impaction
Cough Retrosternal pain
Dysphagia
Regurgitation
Vomiting
Nausea
Pharyngitis/sore throat
Loss of appetite
Refusal to eat
Sleep disorders
Laboratory
findings
Blood eosinophilia
Elevated total IgE
Specific IgE to foods (milk, egg, wheat,
peanut, fish)
Specific IgE to aeroallergens and pollen-related food
allergens
Definition of eosinophilic esophagitis
According to the updated guidelines, EoE is defined
as a chronic, immune-/antigen-mediated disease lim-
ited clinically and pathologically to the esophagus. It
is characterized by symptoms caused by esophageal
dysfunction and, histologically, by eosinophilic in-
flammation. As a general rule, >15 eosinophils per
high-power field (HPF; corresponding to 400× micro-
scope magnification) are diagnostic for EoE [3].
Rising incidence of eosinophilic esophagitis
EoE was initially considered a rare disease. How-
ever, gastroenterologists observed a steady increase
in cases of newly diagnosed EoE. This raised the
question of whether this increase could be attributed
to a higher level of awareness or actually a higher
incidence. An epidemiological study showed that
there was indeed a rising incidence [4, 5]. In the
Western world, one now assumes an incidence of
4.4–7.4 per 100,000 inhabitants/year and a prevalence
of 43 per 100,000 [5]. A study in the US revealed an
equally high prevalence in children [6]. Interestingly,
men are the more commonly affected (male:female
ratio of 3:1) [7].
Differing symptoms in adults and children
EoE patients generally present in good general health
and are primarily symptom-free. However, symptoms
manifest upon ingestion of solid foods. Symptoms are
typically age-dependent (Table 1). Whereas infants
exhibit fussing, feeding problems, abdominal pain,
and failure to thrive, older children experience dys-
phagia, chest pain, and spontaneous bolus obstruc-
tion. In adults, symptoms are limited to dysphagia
upon eating hard, dry foods and after eating too fast,
as well as occasional retrosternal pain. A third of all
untreated EoE patients experience long-lasting bolus
obstruction. By employing certain adaptive strategies,
such as eating slowly, chewing food for a long time,
flushing food down with fluids, as well as avoiding
bread and meat, patients are able to cope with their
disease and are unaware of their dysphagia and its
potential clinical significance.
Diagnostic methods
With the exception of occasional cases of failure to
thrive in children, the clinical examination is gener-
ally normal, while peripheral blood eosinophilia may
or may not be observed. Therefore, endoscopy and
biopsies are essential for establishing a diagnosis [3].
A number of endoscopic findings are typical for EoE,
yet non-pathognomonic: longitudinal furrows and ex-
udates as a sign of acute inflammation, crêpe paper-
like mucosa, as well as protruding ring-like structures
and strictures in a chronic course (Table 2; Fig. 1;
[9]). Endoscopy is combined with biopsy isolation.
Since eosinophil inflammation does not affect the en-
tire esophagus, but rather individual areas, it is impor-
tant that biopsies be taken from a variety of proximal
and distal sites. Taking at least six esophageal biopsies
is recommended.
Histology reveals a thickening of the epithelium
and spongiosis (Table 2). Since the esophagus does
not usually harbor eosinophils, their infiltration in the
epithelium, where they are found as isolated cells, in
groups, or even in small abscesses, is abnormal [9].
The same diagnostic threshold value of 15 eosinophils
per HPF in areas of severe inflammation applies to
both adults and children.
The complex and invasive procedure of endoscopy,
isolation of biopsies, and histology is still indispens-
able for the diagnosis and follow-up of EoE, since
reliable biomarkers or alternative, non-invasive test
methods are not available in routine practice, though
some patients can exhibit eosinophilia in peripheral
blood.
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Table 2 Endoscopic and
histological characteristics
of eosinophilic esophagitis
Finding Interpretation
Endoscopy Exudate Inflammation
Edema Inflammation
Longitudinal furrows/ridges Inflammation
Rings Remodeling, fibrosis
Strictures Remodeling, fibrosis
Histology Eosinophil infiltration (>15 eosinophils/HPF)
Eosinophil abscesses
Luminal eosinophil layer
Altered epithelial surface
Dilated intercellular spaces (spongiosis)
Dyskeratotic epithelial cells
Basal zone hyperplasia
Fibrosis of the lamina propria
Fig. 1 Endoscopic findings in eosinophilic esophagitis (EoE).aAcute inflammatoryEoEwithedema,white exudate, and furrows;
b rings;c strictures in achronic course
In order to establish the severity of EoE, gastroen-
terologists use an endoscopy-based activity score [10].
This score shows relatively good concordance with
a symptom-based patient score which uses an esti-
mation of dysphagia, adaptive behavior due to EoE,
and pain on swallowing [11]. However, in clinical
remission, there may be a discrepancy between the
symptom score and endoscopic and histological ac-
tivity score [12].
Impaired epithelial barrier and T-helper 2 inflam-
mation
Characterization of the inflammatory infiltrate and cy-
tokine pattern showed that a T-helper 2 (Th2) reac-
tion underlies EoE [13]. In addition to eosinophils,
an increased number of interleukin (IL)-5 expressing
T cells, B cells, mast cells with surface-bound IgE, and
dendritic cells have been found in esophageal tissue.
IL-5 increases the production, activation, and survival
of eosinophils. In addition to tumor necrosis factor
(TNF)-alpha, an increased expression of eotaxin, re-
sponsible for the recruitment of eosinophils in tissue,
has been identified. Epithelial cells in EoE tissue pro-
duce increased levels of thymic stromal lymphopoi-
etin (TSLP), which is known to trigger a Th2 immune
response [14]. In line with this, it was shown that IL-
13 plays an important role in the pathogenesis of EoE
[15].
Impaired epithelial barrier function appears to be
a key factor in EoE pathogenesis, similar to atopic
dermatitis. An abnormal expression of desmogleins,
claudin, cadherin, occludin, filaggrin, keratins, and
antimicrobial peptides has been observed in EoE
patients [14, 16–19]. Moreover, an imbalance of pro-
teases, e. g., kallikrein 5 and 7, and protease inhibitors
such as lymphoepithelial Kazal-type-related inhibitor
(LEKTI), appears to be present (unpublished data).
An inverse correlation between the expression levels
of LEKTI and the number of eosinophils producing
eosinophil extracellular traps (EETs) has been ob-
served [14]. Using EETs, which are extracellular DNA
traps that bind toxic granule proteins, eosinophils
are able to kill bacteria in a targeted manner [20,
21]. Subepithelial deposits of extracellular matrix
proteins and a subsequent remodeling and fibrosis
are the main characteristics of EoE. It is likely that
eosinophils are involved in this process, e. g., via
the release of transforming growth factor (TGF)-beta
[22]. The reduction in numbers of tissue eosinophils
following treatment correlates with a reduction in
fibrosis [23, 24].
Thus, the following scenario seems reasonable
(Fig. 2): owing to an impaired epithelial barrier, mi-
crobes and allergens are able to attach and or pene-
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Fig. 2 Pathomechanisms of eosinophilic esophagitis (EoE).
Epithelial barrier impairment develops due to genetic predis-
position and in consequence of reflux and food intake. Invad-
ing allergens and microbial antigens cause activation of the in-
nate and acquired immune system. Eosinophils degranulate,
release toxic proteins, and generate extracellular DNA traps,
whichserveasadefensesystembutalso cause tissuedamage.
By releasing cytokines, eosinophilsmodulate inflammationand
promote its chronification, ultimately with fibrosis, all of which,
in turn, have negative effects on skin barrier function. PAR-
2 protease-activated receptor 2,TLR toll-like receptor,DCden-
dritic cell, IL interleukin, TSLP thymic stromal lymphopoietin,
TGF-β transforminggrowth factor-beta, IgE immunoglobulinE
trate the epithelium. They are recognized by epithelial
cells via pattern recognition receptors (PRR), which
then release cytokines such as TSLP, which in turn
initiate a Th2 inflammation. Eosinophils recruited
to the tissue participate in defense by releasing toxic
granule proteins via degranulation and/or in associ-
ation with EETs. In addition, eosinophils stimulate
the production of inappropriate extracellular matrix
proteins and are thus involved in esophageal fibrosis
in EoE. It is likely that eosinophils primarily perform
a defense function by forming a second (toxic gran-
ule proteins) and, in the case of impaired epithelial
barrier function, a third (fibrotic) barrier. Simultane-
ously, eosinophils can cause collateral damage to the
esophageal epithelium through the release of the toxic
granule proteins and contribute to the perpetuation
of inflammation.
Association with atopic disease
As early as the first publications describing EoE, men-
tion was made of the frequent occurrence of con-
comitant atopic disease [2]. We have found such as-
sociations in 68% of adult EoE patients [25]. Inter-
estingly, patients reported that their allergic airway
disease manifested prior to EoE [25]. Studies with
EoE in children and adults have shown that approxi-
mately 70% exhibit elevated total blood IgE levels [25,
26]. However, varying sensitization patterns depend-
ing on age have been observed. In children, sen-
sitizations to food allergens such as milk, eggs, soy,
wheat/rye, beef, and peanuts predominate [27]. The
incidence of sensitization to foods declines with in-
creasing age and sensitizations to pollen emerge [28].
IgE against environmental allergens are detected in
around 90% of the adult EoE patients. Pollen aller-
gens predominate among the sensitization patterns in
adults, whereas sensitization to purely food allergens
are rare [25]. In contrast, pollen-related food sensiti-
zations—mostly to proteins homologous to the birch
pollen allergens Bet v 1 and Bet v 2, namely PR-10
proteins and profilins—have been observed [29, 30].
It is worthy of note that a local immunoglobulin class
switch and local IgE production can also occur in EoE
[31].
Genetics
The fact that EoE families exist, that male patients pre-
dominante, that most patients have atopic diseases
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and IgE sensitization, and that the Caucasian popula-
tion is particularly affected suggests a genetic dispo-
sition. Interestingly, sporadic and familial EoE are ex-
tremely similar in terms of their clinical, endoscopic,
and histopathological presentation, as well as their
esophageal transcriptome profile [7]. The analysis of
candidate genes revealed that single nucleotide poly-
morphisms (SNPs) of the eotaxin, TGF-beta, and fi-
laggrin genes were striking in EoE patients [32–34].
Moreover, in addition to TSLP gene polymorphisms,
a polymorphism in the TSLP receptor gene on Xp22.3
and Yp11.3 has been described, which would also at
least partially explain EoE’s predominance in males
[35]. A genome-wide association study identified the
5q22 and 2p23 loci spanning the gene for calpain 14,
a protease expressed in the esophagus, as a risk factor
for EoE [36, 37]. It can be assumed that EoE is a poly-
genetically determined disease with complex inheri-
tance.
EoE: a non-IgE-mediated food intolerance
The question is whether sensitizations, particularly
those to food, play a role at all in the pathogenesis
of EoE. Because of the high rate of sensitization and
the clinical response to elimination diets, IgEs against
food were suggested as playing a direct role. However,
the determination of specific IgEs and/or skin prick
tests appear inadequate to identify the EoE-eliciting
allergens [27, 38]. The positive and negative predictive
values of foods vary considerably, averaging 50–92%
and 41–100%, respectively [39]. Diets geared towards
eliminating these type I allergens do not by any means
result in significant improvements of symptoms in all
patients [27, 38–40]. Adult EoE patients sensitized to
grass pollen, wheat, and rye did not respond to an
elimination diet in which cereals were avoided over
a 6-week period [40]. It should also be mentioned
that administration of a monoclonal anti-IgE antibody
did not result in a significant treatment effect in pe-
diatric and adult EoE patients [41]. It is clear from
clinical experimental data that EoE is not a typical,
purely IgE-mediated disease; rather, one sees char-
acteristics of EoE found in hypersensitivity reactions,
in mostly T cell-mediated skin diseases, e. g., allergic
contact dermatitis, drug eruptions, atopic dermatitis
triggered by food, or chronic inflammatory bowel dis-
eases [42]. In terms of clinical practice, this means
that skin prick tests and the determination of specific
IgE to food are not useful for identifying triggers of
EoE. However, there is a rationale for their use to in-
vestigate concomitant allergic disease.
New in the EoE spectrum: PPI-responsive eso-
phageal eosinophilia
Like EoE, gastroesophageal reflux disease (GERD)
can also be associated with eosinophil infiltration of
the esophagus, which is why symptoms, treatment re-
sponse, and histological response to PPI were formerly
considered diagnostic criteria for GERD. A detailed
investigation in patients with histologically proven
eosinophil infiltration of the esophagus and response
to PPI therapy showed that 75% achieved clinical re-
mission, two thirds of whom exhibited a GERD profile
(eosinophilic infiltration <35/HPF, signs of reflux on
endoscopy, or pH measurement) and one third an
EoE profile (eosinophilic infiltration >35/HPF, typical
EoE symptoms, and endoscopy findings) [43]. At least
a transient response to PPI has also been observed in
children with EoE [44]. Transcriptome analysis was
able to show that allergic inflammation resolves if
esophageal eosinophilia responds to PPI [45]. The
controversy over the extent to which PPI-responsive
esophageal eosinophilia (PPI-REE) differs from EoE
persists. According to a recently published consensus
paper, the following arguments speak for PPI-REE
more likely being a continuum of EoE rather than
a separate entity [46]:
● There is no clinical, endoscopic, or histological dis-
tinction between PRI-REE and EoE.
● Th2-typical gene expression and inflammation are
found in both PPI-REE and EoE patients.
● PPI reduces Th2 inflammation in PPI-REE in the
same way as corticosteroids do with EoE.
● EoE patients may respond to diets and topical corti-
costeroids as well as to PPI.
Recent discovery: an eosinophilic esophagitis-
like disease
In recent years, we have observed members of four
EoE families with an EoE-like disease [47]. They ex-
perienced symptoms including the esophageal dys-
function typical of EoE, but exhibited no, or only dis-
crete, lesions in the esophageal mucosa on endoscopy.
Histologically, T and mast cell infiltration was strik-
ing, while eosinophils were conspicuous for their ab-
sence. Less expression of eotaxin, TNF-alpha, and
TSLP was noted as compared with EoE. Expression
analysis of 94 mRNA transcripts showed a picture sim-
ilar to EoE-like disease and EoE. However, mRNA ex-
pression of mucin 4 (MUC4) and cadherin 26 (CDH26)
enabled a distinction between EoE-like disease and
healthy controls, while another difference was seen
between EoE and EoE-like disease in the mRNA ex-
pression of eotaxin. Interestingly, four of the five pa-
tients described with EoE-like disease were females,
all of whom had offspring developing EoE in the first
generation, suggesting the possibility of a hereditary
disease. In summary, the evidence suggests that the
two diseases have a similar pathogenesis.
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Table 3 Treatmentof
eosinophilic esophagitis
Intervention Children Adults Comment
PPI x x Initially 8–12 weeks
Corticosteroids Systemic x x –
Oral x x Initial and maintenance therapy
Diet SFED x x Re-exposure test
FFED x x Re-exposure test
“Elemental” x x –
Dilation x x In stenosis, no anti-inflammatory effect
Bolus removal Endoscopic x x –
SSFD six-food elimination diet, FFED four-food elimination diet, PPI proton pump inhibitors
EoE in adults and children: one entity or distinct
entities?
Epidemiological, clinical, and pathogenetic studies
have always made a distinction between pediatric
and adult EoE. Apart from clinical symptoms being
more diffuse and the less likely occurrence of bolus
obstruction in children, as well as the IgE sensitiza-
tion spectrum, no significant differences are seen in
terms of endoscopic findings, histology, pathogenesis,
or response to drug therapy and dietary measures [8].
Remodeling resulting in the strictures and narrow-
ing of the esophagus as seen by endoscopy is more
frequently observed in adults as compared to chil-
dren, which is most likely attributable to their longer
duration of disease [48].
Treatment
The treatment of EoE should have the following aims:
remission of symptoms, control of inflammation, im-
provement of quality of life, prevention of hazardous
bolus impaction, and, as a result, avoidance of long-
term structural and functional damage (Table 3).
Proton pump inhibitors
Since on average 60 and 50% of patients with esopha-
geal eosinophilia respond to PPI treatment either with
a clinical improvement or histological remission, re-
spectively, PPI have recently been recommended for
treatment initiation (1–2 standard doses once to twice
daily for 8–12 weeks) [3, 49]. PPI are able to treat not
only existing or concomitant GERD, but also PPI-REE.
However, since only few studies on PPI are available as
yet and there are also no reliable, direct comparative
studies with the far better evaluated topical corticos-
teroids, it is not yet possible to position PPI in the
treatment algorithm for EoE.
Corticosteroids
A prospective controlled study in children showed that
oral prednisone was as effective as high-dose topi-
cal fluticasone in achieving a clinical and histologi-
cal remission of EoE [50]. Both topical and systemic
corticosteroids are used for initial treatment in active
EoE, as well as for maintenance treatment, whereby
the type, strength, and dose are determined accord-
ing to disease severity, availability, and practicability
from the patient’s perspective [3]. Swallowed cortico-
steroids (budesonide, fluticasone) adhere well to the
esophagus and are thus highly effective, as shown in
studies with a treatment period of 2–12 weeks [51, 52].
Alternatively, corticosteroid aerosols can be used [53].
For adults, the results of a long-term treatment study
(up to 50 weeks) with low-dose oral budesonide are
available [24]. Inhibiting inflammation using corti-
costeroids reduces the risk of long-lasting bolus im-
pactions [54].
Biologicals
Based on the immunopathogenesis of EoE, several
approaches for targeted treatment have emerged.
The administration of mepolizumab, an anti-IL-5 an-
tibody, achieved a marked reduction of blood and
tissue eosinophils in both children and adults; the
clinical effect, however, was minimal [23, 55]. Treat-
ment with an anti-TNF-alpha antibody failed to show
the expected effect, despite the fact that high TNF-al-
pha production by the epithelium is seen in EoE [56].
Although the majority of EoE patients exhibit IgE sen-
sitization to direct or pollen-related food allergens,
treatment with the anti-IgE antibody omalizumab did
not elicit any significant effect in terms of reducing
symptoms and inflammation, a finding which again
supports the presumption that EoE is a non-IgE-me-
diated disease [41]. Thus, it is currently assumed that
the pathogenesis of EoE is highly complex and that
merely eliminating one mediator is not sufficient for
an effective treatment. The results of IL-13 and/or
IL-4 blockade are eagerly awaited. A pilot study on
23 patients with EoE demonstrated that treatment
with an anti-IL-13 antibody was superior to placebo
in terms of clinical and histological response [57].
Diets
A study published as early as 1995 made the observa-
tion that children with EoE responded extremely well
to an elemental diet comprised of amino acid-based
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dairy products; symptoms, however, recurred upon
reintroduction of certain food proteins [58]. This ele-
mental diet is highly effective, not only in EoE, but also
in inflammatory bowel disease, which is why a gen-
erally anti-inflammatory mechanism is suspected [8].
Meanwhile, the effectiveness of an elemental diet has
also been proven in adults [59]. Unfortunately, the
practical implementation of an elemental diet is time-
consuming and expensive. For this reason, it is used
primarily in severe and treatment-refractory cases. In
contrast, an empirical diet involving the elimination
of milk, eggs, soy, wheat, peanuts, tree nuts, fish, and
shellfish (six-food elimination diet) is able to resolve
symptoms and histological changes in over 70% of
children and adults affected by EoE [60, 61]. Re-ex-
posure to wheat and milk (in 60 and 50% of cases, re-
spectively) usually caused EoE recurrence, while con-
cordance with specific IgE levels was seen in only 13%
[61]. Recently, a four-food elimination diet, including
the elimination of dairy products, wheat, eggs, and
legumes, has been tested [62]. The clinicopathological
remission rate was 54%; milk, eggs, and wheat were
identified as triggers in 50, 36, and 31% of patients,
respectively, in re-exposure testing [62].
Dilation
Dilation is used for patients with an inadequate re-
sponse to drug therapy or dietary measures, and in
whom a functionally relevant narrowing of the esoph-
agus has developed. When performed carefully using
a flexible endoscope, dilation is a safe method [63]. It
is important to note that dilation is a mechanical in-
tervention and has no effect on eosinophilic inflam-
mation.
Tasks for the future
EoE has been known as a distinct disease entity for
only around 25 years, and the effort that has gone into
characterizing it clinically, endoscopically, and histo-
logically, as well as into deciphering its pathogenesis
and finding effective treatments, is enormous. What
are the urgent questions/problems that need to be
addressed?
● EoE can be considered as a spectrum of diseases
characterized by eosinophil infiltration of the esoph-
agus. What subtypes can be distinguished clinically,
histologically, and in terms of treatment response?
How can EoE be distinguished from other diseases,
e. g., GERD, in the differential diagnosis?
● To date, endoscopy has been essential for establish-
ing the diagnosis and monitoring treatment. There
is an urgent need for non-invasive methods and
biomarkers for routine practice. The development
of the string test, in which inflammatory media-
tors that adhere to a piece of “swallowed” string are
extracted and quantitatively measured, promises
progress in this direction [64].
● What benefits can the use of omic technologies,
e. g., creating transcriptome profiles for blood and
tissue, confer?
● Changes in the esophageal microbiome, such as
an absolute increase in the number of bacteria and
a relative predominance of Haemophilus have been
identified in EoE [65]. What are the effects of these
changes and how can they be prevented or regu-
lated?
● EoE is associated with food intolerance [42]. What
are the underlying mechanisms? What are the diag-
nostic possibilities and dietary consequences?
● The effects of treatments used to date, e. g., cortico-
steroids, are broad and non-specific. Future treat-
ments should interferewith the pathomechanismof
EoE in a targeted manner, i. e., should be effective
with few side effects and be practical in their appli-
cation.
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